Published: Aug, 2016
The global market for HPV and CMV therapeutics features numerous healthcare industry giants such as Roche AG, Valeant Pharmaceuticals, AbbVie Inc., Fresenius Kabi USA, Perrigo Company plc, Actavis plc, Fougera Pharmaceuticals, and Merck & Co. According to Transparency Market Research, Valeant Pharmaceuticals, Fougera Pharmaceuticals, and Perrigo Company plc held a dominant 89.2% share in the global HPV therapeutics market in 2013, while the leaders in the CMV therapeutics market were Roche AG, Clinigen Group plc, and Fresenius Kabi USA, who collectively accounted for 93% of the market.
The key opportunity for manufacturers of HPV and CMV therapeutics is the development of biologics and drugs with a low risk of possible toxicity. HPV therapeutics, in particular, have benefited immensely from the growing awareness about the adverse effects of the HPV vaccine. On the other hand, the CMV therapeutics is set to witness a growing demand for CMV vaccines, leading to players operating in both markets having to establish research into both product lines. This could result in increased consolidation of the HPV and CMV therapeutics market in the coming years, as smaller players may not be able to afford developing both product lines.
Expanding Healthcare Sector in Emerging Economies to Drive Demand for HPV, CMV Therapeutics
The prime driver for the global HPV and CMV therapeutics market is the increasing prevalence of both diseases in emerging regions such as Asia Pacific and Latin America. The ongoing cultural shift in these regions has contributed to an increase in the prevalence of sexually transmitted diseases and is thus a driver for the HPV therapeutics market. Thanks to the rapid ongoing development of the healthcare sector, developing regions present lucrative opportunities for manufacturers of both HPV and CMV therapeutics. This has led to many leading market players focusing on maximizing their performance in underdeveloped/developing economies.
The increasing demand for replacements for HPV vaccines is another key driver for the global HPV therapeutics market. Digestive distress, fever, headaches, and skin irritations at the site of the injection are some of the side effects of the HPV vaccine. The growing awareness regarding the risk of the same has resulted in growing public demand for HPV therapeutics instead.
Lack of Awareness in Key Markets Hurting HPV, CMV Therapeutics Market
On the other hand, despite the advancements in the healthcare sector, the lack of awareness about the etiology and treatment of HPV and CMV is hampering the market in emerging regions, as the rate of diagnosis among patients is quite low. This is a key restraint for the HPV and CMV therapeutics market in the coming years and is likely to be ameliorated by sustained efforts from healthcare bodies as well as manufacturers of HPV and CMV therapeutics.
Genital Warts to Remain Leading Application of HPV Therapeutics
Of the various ways in which HPV manifests, genital warts are the leading demand driver for HPV therapeutics. The high number of HPV strains that can cause genital warts, particularly when the disease is contracted through sexual contact, is responsible for the dominant share of the genital warts segment in the HPV therapeutics market.
By drug class, ganciclovir and valganciclovir dominate the demand from the CMV therapeutics market, while immunomodulators are the leading class of drugs prescribed for HPV.
Geographically, North America is the leading market for HPV and CMV therapeutics, with the regional HPV therapeutics market’s revenue expected to reach US$597.3 mn and the CMV therapeutics market’s revenue expected to reach US$202.2 mn by the end of 2016. Despite the substantial growth prospects of the Asia Pacific and Latin America markets for HPV and CMV therapeutics, the growing sexually active population and the ease of obtaining diagnostics and therapeutics in North America are likely to keep the latter dominant in the coming years.
The global markets for HPV and CMV therapeutics are expected to reach a valuation of US$2.3 bn and US$0.9 bn, respectively, by 2020. The information presented in this review is based on a Transparency Market Research report, titled, ‘Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.’
The global HPV and CMV therapeutics market is segmented as follows:
HPV Therapeutics Market, by Drug Class
- Anti-neoplastic agents
- Keratolytic Agents
HPV Therapeutics Market, by Application
- Genital warts
- Genital cancer
- Oral papillomas
- Epidermodysplasia verruciformis
CMV Therapeutics Market, by Drug
CMV Therapeutics Market, by Application
- CMV retinitis
- Gastrointestinal ulcers
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453